Table 3 Rank, standard gamble utility scores and intraclass correlation coefficient for cervical cancer prevention health states
From: A survey of population-based utility scores for cervical cancer prevention
Cervical cancer duration | ||||||
|---|---|---|---|---|---|---|
Health state | Median rank | 12 months | Lifetime | |||
Mean utility score | Median utility score | Mean utility score | Median utility score | Intraclass correlation coefficient | ||
(IQR ) | (SE) | (IQR) | (SE) | (IQR) | ||
Cytology normal | 1 | 0.9967 | 0.9998 | 0.9995 | 1.0 | 0.13 |
(1-2) | (0.0026) | (0.9994 - 1.0) | (0.0002) | (0.9998 -1.0) | ||
HPV vaccination | 1 | 0.9750 | 0.9998 | 0.9978 | 1.0 | 0.07 |
(1-2) | ( 0.0244) | (0.9996 - 1.0) | (0.0018) | (0.9998 - 1.0) | ||
LG cytology | 3 | 0.9735 | 0.9997 | 0.9980 | 1.0 | 0.05 |
(3-5) | (0.0231) | (0.9994 - 1.0) | (0.0017) | (1.0 -1.0) | ||
LG cytology with colposcopy normal | 4 | 0.9724 | 0.9997 | 0.9970 | 0.9999 | 0.08 |
(3-6) | (0.0226) | (0.9964 - 0.9999) | (0.0017) | (0.9997 - 1.0) | ||
HPV positive with cytology normal | 4 | 0.9733 | 0.9997 | 0.9970 | 0.9999 | 0.02 |
(3-6) | (0.0233) | (0.9977 - 0.9999) | (0.0017) | (0.9997 - 1.0) | ||
HPV positive with colposcopy normal | 5 | 0.9964 | 0.9997 | 0.9991 | 0.9999 | 0.22 |
(3-6) | ( 0.0021) | (0.9984 - 0.9999) | (0.0004) | (0.9997 - 1.0) | ||
Treated genital warts | 5 | 0.9700 | 0.9997 | 0.9969 | 0.9998 | 0.09 |
(3-7) | ( 0.0244) | (0.9969 - 0.9999) | (0.0019) | (0.9997 - 1.0) | ||
HG cytology with CIN 1 | 6 | 0.9724 | 0.9997 | 0.9953 | 0.9999 | 0.01 |
(4-8) | (0.0226) | (0.9970 - 0.9999) | (0.0027) | (0.9997 - 1.0) | ||
HG cytology with CIN 2 or 3 | 7 | 0.9704 | 0.9996 | 0.9970 | 0.9999 | 0.12 |
(6-9) | (0.0233) | (0.9959 - 0.9999) | (0.0018) | (0.9994 - 1.0) | ||
Early stage cervical cancer | 10 | 0.8178 | 0.9450 | 0.9714 | 0.9900 | 0.78 |
(8-10) | (0.0531) | (0.915 - 0.995) | (0.0052) | (0.9450 - 0.9950) | ||